Anti-ANG2 & VEGFA Antibody (Vanucizumab)
Catalog No.
F2091
Anti-ANG2 & VEGFA Antibody (Vanucizumab)
Featured Products
Vanucizumab is a first-in-class bispecific IgG1 monoclonal antibody that simultaneously blocks the interaction of VEGF-A and angiopoietin-2 (Ang-2) with their receptors. Vanucizumab has anti-angiogenic and anti-cancer effects.
Quality Control & DataSheet
- View current batch:
-
Purity > 95% by SDS-PAGE and SEC-HPLC analyses.
- MSDS (Material Safety Data Sheet)
- Datasheet
146.89 kDa
Dry ice
1448221-05-3
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
RO-5520985, RG-7221, B800Z06O8K
100 mM Pro 20 mM Arg pH 5.0. No preservative!
Q9UID3 & P15692
Human
Unconjugated
Monoclonal
Protein A
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
Immobilized human VEGF165 His at 2 ug/mL can bind Anti-ANG2 & VEGFA Reference Antibody (Vanucizumab)
ANG2 & VEGFA
Please avoid freeze-thaw cycles.